Begins Coverage on NeuroMetrix (NASDAQ:NURO) began coverage on shares of NeuroMetrix (NASDAQ:NUROFree Report) in a research report report published on Wednesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 1.2 %

NASDAQ NURO opened at $3.82 on Wednesday. The firm has a market capitalization of $7.67 million, a PE ratio of -0.61 and a beta of 2.16. The business’s 50-day moving average price is $4.06 and its two-hundred day moving average price is $3.70. NeuroMetrix has a 12 month low of $2.70 and a 12 month high of $9.20.

NeuroMetrix (NASDAQ:NUROGet Free Report) last announced its earnings results on Wednesday, May 15th. The medical device company reported ($1.67) EPS for the quarter. The company had revenue of $1.09 million during the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative return on equity of 39.85%.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC purchased a new position in shares of NeuroMetrix, Inc. (NASDAQ:NUROFree Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned 2.80% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is owned by institutional investors.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

Read More

Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with's FREE daily email newsletter.